Uroplasty, Inc.  

(Public, NASDAQ:UPI)   Watch this stock  
Find more results for Larry B. Lee´┐Ż
3.37
+0.11 (3.37%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.29 - 3.48
52 week 1.69 - 5.40
Open 3.29
Vol / Avg. 25,661.00/41,645.00
Mkt cap 72.91M
P/E     -
Div/yield     -
EPS -0.25
Shares 21.64M
Beta -1.45
Inst. own 55%
May 26, 2014
Q4 2014 Uroplasty, Inc. Earnings Release (Estimated) Add to calendar
Mar 11, 2014
Uroplasty, Inc. at ROTH Conference - Webcast
Jan 23, 2014
Q3 2014 Uroplasty, Inc. Earnings Conference Call - Webcast
Jan 23, 2014
Q3 2014 Uroplasty, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -10.48% -14.74%
Operating margin -10.23% -14.73%
EBITD margin - -9.58%
Return on average assets -15.42% -15.62%
Return on average equity -19.10% -18.40%
Employees 96 -
CDP Score - -

Address

5420 Feltl Rd.
MINNETONKA, MN 55343
United States - Map
+1-952-4266140 (Phone)
+1-952-4266171 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Uroplasty, Inc. is a medical device company. The Company develops, manufactures and markets products for the treatment of voiding dysfunctions. Its primary focus is on two products: the Urgent PC Neuromodulation System, which is minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation (PTNS) for office-based treatment of overactive bladder (OAB) and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence, and Macroplastique Implants, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, its Urgent PC System is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence, fecal incontinence, vocal cord rehabilitation and vesicoureteral reflux.

Officers and directors

James P. Stauner Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Robert E. Kill President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Brett A. Reynolds Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Susan Hartjes Holman Chief Operating Officer, Secretary
Age: 58
Bio & Compensation  - Reuters
Suranjan Roychowdhury Vice President - Research & Development and Clinical Affairs
Bio & Compensation  - Reuters
Larry Heinemann Vice President - Sales
Age: 60
Bio & Compensation  - Reuters
Nancy A. Kolb Vice President - Global Marketing
Age: 62
Bio & Compensation  - Reuters
David B. Perry Vice President - Marketing
Bio & Compensation  - Reuters
Marc M. Herregraven Vice President - Manufacturing
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Arie J. Koole Corporate Controller, Managing Director - Dutch Operations
Age: 48
Bio & Compensation  - Reuters